In the News

The Feed Insider interviewed Dr. Brianna Stubbs on the power of ketones and how they can be leveraged for performance and cognitive health. The blog post covers the below key...

New CEO set to Marshall longevity with a pipeline that delivers immediate therapeutic benefit, but always has an eye on a future preventative angle. Back in January, we reported that...

Biotech company Morphoceuticals has announced it closed an $8 million Seed-2 funding round led by Prime Movers Lab and initial investor Juvenescence.  Seed funding will advance programs using electroceuticals in limb regeneration and...

Juvenescence sponsored this article in Health, which discusses how your body can benefit from an efficient metabolism.

Dr. Greg Bailey, MD, CEO of Juvenescence, conducts an interview with M2Bio Sciences. In the interview, Greg shares his insights on Juvenescence, longevity biotech, entrepreneurship, and his personal story.

Michael Hufford, CEO of LyGenesis, speaks with Longevity Technology about revolutionary regenerative technology and plans for clinical development.  

Jim Mellon, Chairman of Juvenescence, speaks with Barclays as part of the ‘Beyond 100’ program, about the science of longevity and the implications of living until 120 years.

Dr. Greg Bailey, MD gives an interview to Longevity Technology on near-term longevity breakthroughs, including the latest developments at Juvenescence and dealing with the impact of COVID-19.   

Relation Therapeutics and Mila, the Montreal-based AI research institute are collaborating on a new project targeting the development of COVID-19 therapeutics funded by the Bill & Melinda Gates Foundation.   

LyGenesis CEO Michael Hufford talks to Longevity Technology about Longevity research programs and investment.

MDI’s expertise will help fight coronary heart disease, thrombosis, and chronic fibrotic and inflammatory diseases.

MDI’s expertise will help fight coronary heart disease, thrombosis, and chronic fibrotic and inflammatory diseases.